High doses of targeted radiation with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] do not correlate with incidence of mucositis, febrile neutropenia or sepsis in the prospective, randomized phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia Meeting Abstract
| Authors: | Gyurkocza, B.; Nath, R.; Choe, H.; Seropian, S.; Stiff, P. J.; Abhyankar, S.; Agura, E.; Litzow, M.; Tomlinson, B. K.; Chen, G. L.; Hari, P.; Orozco, J.; Al-Kadhimi, Z. S.; Abboud, C.; Van Besien, K.; Sabloff, M.; Magalhaes-Silverman, M. M.; Foran, J. M.; Schuster, M. W.; Kebriaei, P.; Levy, M.; Lazarus, H. M.; Giralt, S. A.; Liang, Q.; Berger, M. S.; Reddy, V.; Pagel, J. M. |
| Abstract Title: | High doses of targeted radiation with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] do not correlate with incidence of mucositis, febrile neutropenia or sepsis in the prospective, randomized phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547203284 |
| DOI: | 10.1182/blood-2020-134624 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 30 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
